(Q83961760)

English

Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects

scientific article published on 01 June 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765179%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765179%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Steven A Kaplan

2

object named as

Steven A Kaplan

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765179%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

author name string

François Giuliano

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765179%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Marie-Josée Cabanis

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765179%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Béatrice Astruc

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765179%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

publication date

1 June 2006

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765179%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765179%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

67

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765179%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765179%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1199-1204

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765179%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative, international overview

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.001

7 January 2021

Practice trends in the diagnosis and management of benign prostatic hyperplasia in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.001

7 January 2021

Overview of alpha-blocker therapy for benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.001

7 January 2021

Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.001

7 January 2021

Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.001

7 January 2021

Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7).

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.001

7 January 2021

Epidemiology of erectile dysfunction in four countries: cross-national study of the prevalence and correlates of erectile dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.001

7 January 2021

The association between lower urinary tract symptoms and erectile dysfunction in four centres: the UrEpik study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.001

7 January 2021

Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical "Aging Male" symptoms? Results of the "Cologne Male Survey"

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.001

7 January 2021

Summary of the recommendations on sexual dysfunctions in men.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.001

7 January 2021

Phosphodiesterase type 5 (PDE5) inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.001

7 January 2021

Time course of the interaction between tadalafil and nitrates

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.001

7 January 2021

ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.001

7 January 2021

Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference).

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.001

7 January 2021

Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.001

7 January 2021

Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.001

7 January 2021

Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.001

7 January 2021

AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.001

7 January 2021

Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.001

7 January 2021

Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.001

7 January 2021

Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.001

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.UROLOGY.2006.01.001

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765179%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765179%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q83961760&oldid=1724067270"